Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GMC-252
- Development stage
- Phase 1
- Lead developer
- Genmedica Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
GMC-252 is a small molecule agonist of the G protein-coupled receptor 119 (GPR119) developed by Genmedica Therapeutics for the treatment of Type 2 diabetes mellitus. GPR119 is primarily expressed in pancreatic beta cells and enteroendocrine cells of the gastrointestinal tract. Activation of this receptor stimulates the glucose-dependent secretion of insulin and incretin hormones, such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which collectively improve glycemic control. GMC-252 was investigated in Phase 1 clinical trials as an oral therapy, often formulated as an L-lysine salt to enhance its pharmacokinetic profile. Clinical development focused on assessing its safety, tolerability, and pharmacokinetics in both healthy volunteers and patients with Type 2 diabetes.
- Other names
- GMC-252-L-Lysine saltGMC252-L-Lysine saltGMC 252-L-Lysine saltGMC 252GMC252GMC-252
02
Targets
IKBKB (IKKβ)
Beyond the preview
Go deeper on GMC-252.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GMC-252.